Lack of direct involvement of a diazepam long-term treatment in the occurrence of irreversible cognitive impairment: a pre-clinical approach.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
03 12 2021
03 12 2021
Historique:
received:
26
02
2021
accepted:
25
10
2021
revised:
20
09
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
1
2
2022
Statut:
epublish
Résumé
Several observational studies have found a link between the long-term use of benzodiazepines and dementia, which remains controversial. Our study was designed to assess (i) whether the long-term use of benzodiazepines, at two different doses, has an irreversible effect on cognition, (ii) and whether there is an age-dependent effect. One hundred and five C57Bl/6 male mice were randomly assigned to the 15 mg/kg/day, the 30 mg/kg/day diazepam-supplemented pellets, or the control group. Each group comprised mice aged 6 or 12 months at the beginning of the experiments and treated for 16 weeks. Two sessions of behavioral assessment were conducted: after 8 weeks of treatment and after treatment completion following a 1-week wash-out period. The mid-treatment test battery included the elevated plus maze test, the Y maze spontaneous alternation test, and the open field test. The post-treatment battery was upgraded with three additional tests: the novel object recognition task, the Barnes maze test, and the touchscreen-based paired-associated learning task. At mid-treatment, working memory was impaired in the 15 mg/kg diazepam group compared to the control group (p = 0.005). No age effect was evidenced. The post-treatment assessment of cognitive functions (working memory, visual recognition memory, spatial reference learning and memory, and visuospatial memory) did not significantly differ between groups. Despite a cognitive impact during treatment, the lack of cognitive impairment after long-term treatment discontinuation suggests that benzodiazepines alone do not cause irreversible deleterious effects on cognitive functions and supports the interest of discontinuation in chronically treated patients.
Identifiants
pubmed: 34857741
doi: 10.1038/s41398-021-01718-8
pii: 10.1038/s41398-021-01718-8
pmc: PMC8640018
doi:
Substances chimiques
Diazepam
Q3JTX2Q7TU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
612Informations de copyright
© 2021. The Author(s).
Références
J Clin Neurol. 2019 Jan;15(1):9-19
pubmed: 30375757
J Cereb Blood Flow Metab. 2019 Jun;39(6):1015-1025
pubmed: 29333917
Oxid Med Cell Longev. 2017;2017:3037876
pubmed: 29098059
Neurosci Biobehav Rev. 2005;29(8):1193-205
pubmed: 16084592
J Am Med Dir Assoc. 2020 Feb;21(2):201-211.e2
pubmed: 31653534
Exp Aging Res. 1996 Jan-Mar;22(1):73-81
pubmed: 8665988
Eur J Pharmacol. 2018 Jul 15;831:77-86
pubmed: 29738701
Am J Epidemiol. 2019 Jul 1;188(7):1228-1236
pubmed: 31111865
Neuropharmacology. 2019 Sep 1;155:162-172
pubmed: 31132437
Eur J Neurosci. 1998 Jul;10(7):2380-7
pubmed: 9749766
Behav Brain Res. 2020 Apr 6;383:112501
pubmed: 31987935
J Psychiatry Neurosci. 1992 Jun;17(2):72-7
pubmed: 1637802
Drug Alcohol Depend. 1997 Jul 4;46(3):181-90
pubmed: 9250476
Neurobiol Aging. 2009 Apr;30(4):507-14
pubmed: 19231028
Arch Toxicol. 2010 Dec;84(12):939-46
pubmed: 20130842
Prog Neurobiol. 2014 Feb;113:88-94
pubmed: 23978486
Dialogues Clin Neurosci. 2015 Sep;17(3):295-303
pubmed: 26487810
CNS Drugs. 2016 Jan;30(1):1-7
pubmed: 26715389
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Oct 3;70:68-76
pubmed: 27208614
J Clin Monit Comput. 1999 Dec;15(7-8):529-44
pubmed: 12578052
Presse Med. 2018 Oct;47(10):878-881
pubmed: 30454579
Pharmacogenetics. 1993 Dec;3(6):291-301
pubmed: 8148870
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
J Vis Exp. 2018 Nov 20;(141):
pubmed: 30531711
Neuroscience. 1988 Jun;25(3):771-95
pubmed: 2841624
Eur J Neurosci. 2004 Oct;20(8):2214-24
pubmed: 15450101
Aging (Albany NY). 2015 Jun;7(6):370-82
pubmed: 26081073
CNS Drugs. 2018 Jun;32(6):485-497
pubmed: 29926372
Curr Top Behav Neurosci. 2016;28:449-74
pubmed: 27646012
Anesth Prog. 1980 Nov;27(6):175-83
pubmed: 19598594
BMJ. 2014 Sep 09;349:g5205
pubmed: 25208536
Curr Pharm Des. 2002;8(1):1-3
pubmed: 11812246
JAMA Psychiatry. 2015 Feb;72(2):136-42
pubmed: 25517224
ScientificWorldJournal. 2006 Nov 16;6:1460-5
pubmed: 17115086
Handb Exp Pharmacol. 2008;(182):335-60
pubmed: 18175099
Psychopharmacology (Berl). 1998 Aug;138(3-4):344-53
pubmed: 9725757
Behav Neural Biol. 1991 Jan;55(1):131-6
pubmed: 1996944
BMC Public Health. 2020 Jun 1;20(1):818
pubmed: 32487058
Pharmacol Biochem Behav. 2018 Sep;172:59-67
pubmed: 30030126
Pharmacol Biochem Behav. 2001 Feb;68(2):235-44
pubmed: 11267628
BMC Public Health. 2019 May 14;19(1):566
pubmed: 31088561
Expert Opin Drug Metab Toxicol. 2009 Nov;5(11):1421-33
pubmed: 19689220
Transl Stroke Res. 2021 Apr;12(2):316-330
pubmed: 32440818
Ann Pharmacother. 2020 Mar;54(3):219-225
pubmed: 31595772
Biomed Res Int. 2013;2013:408573
pubmed: 23971034
Psychopharmacology (Berl). 1990;102(3):373-8
pubmed: 1979181
BMC Geriatr. 2019 Oct 21;19(1):276
pubmed: 31638906
Neuropharmacology. 2019 Jan;144:319-326
pubmed: 30408486
J Pharmacol Toxicol Methods. 2006 Sep-Oct;54(2):99-105
pubmed: 16750402
Z Gerontol Geriatr. 2014 Jun;47(4):279-84
pubmed: 25088385
Eur Addict Res. 2019;25(6):320-329
pubmed: 31494655
JAMA Netw Open. 2020 Oct 1;3(10):e2019029
pubmed: 33119104